Investigational drug · Phase 3
Pridopidine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis, Huntington Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "Pridopidine"
First trial start
2026
Feb 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pridopidine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis
- Huntington Disease
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Huntington's disease chorea · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pridopidine" as an intervention, largest first.
- HEALEY ALS Platform Trial - Master ProtocolPivotal-lookingActive, not recruiting
Merit E. Cudkowicz, MDAcademic, hospital or other
NCT04297683 · 1,500 participants (planned) · Start Jun 14, 2020 · Primary completion Jul 2027
Drug: Zilucoplan; Verdiperstat and 6 more · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 81 sites in all
- Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPivotal-lookingRecruiting
PrileniaIndustry
NCT07322003 · 500 participants (planned) · Start Feb 1, 2026 · Primary completion Mar 2028
Drug: Pridopidine; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; San Francisco, California; Aurora, Colorado · 56 sites in all
- PRidopidine's Outcome On Function in Huntington Disease, PROOF- HDPivotal-lookingCompleted
PrileniaIndustry
NCT04556656 · 499 participants · Start Oct 16, 2020 · Primary completion Mar 14, 2023
Drug: Pridopidine; Placebo · For: Huntington Disease
Sites: Davis, California; San Diego, California; Englewood, Colorado · 58 sites in all
- A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's DiseasePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT00665223 · 437 participants · Start Apr 24, 2008 · Primary completion Jun 14, 2010
Drug: ACR16; Placebo · For: Huntington's Disease
Sites: Graz, Austria; Innsbruck, Austria; Leuven, Belgium · 31 sites in all
- A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's DiseasePivotal-lookingCompleted
PrileniaIndustry
NCT02006472 · 408 participants · Start Feb 28, 2014 · Primary completion Dec 16, 2015
Drug: Pridopidine · For: Huntington's Disease
Sites: La Jolla, California; Los Angeles, California; Englewood, Colorado · 58 sites in all
- Pridopidine Phase 3 Study in Huntington's DiseasePivotal-lookingRecruiting
PrileniaIndustry
NCT07609108 · 400 participants (planned) · Start Jul 1, 2026 · Primary completion Jun 2028
Drug: Pridopidine; Placebo · For: Huntington Disease
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 66 sites in all
PrileniaIndustry
NCT02494778 · 248 participants · Start Sep 24, 2015 · Primary completion Jan 12, 2018
Drug: Pridopidine · For: Huntington's Disease
Sites: Los Angeles, California; Englewood, Colorado; Washington D.C., District of Columbia · 46 sites in all
- A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's DiseasePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT00724048 · 227 participants · Start Oct 24, 2008 · Primary completion Jul 26, 2010
Drug: ACR16 · For: Huntington Disease
Sites: Birmingham, Alabama; San Diego, California; Littleton, Colorado · 28 sites in all
- HEALEY ALS Platform Trial - Regimen D PridopidinePivotal-lookingCompleted
Merit E. Cudkowicz, MDAcademic, hospital or other
NCT04615923 · 163 participants · Start Dec 18, 2020 · Primary completion Jul 14, 2022
Drug: Pridopidine; Matching Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Boston, Massachusetts
- Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington DiseaseCompleted
PrileniaIndustry
NCT01306929 · 134 participants · Start Mar 24, 2011 · Primary completion Jan 5, 2018
Drug: pridopidine · For: Huntington Disease
Newest research
PubMed records naming it or its code names, newest first.
- Antidopaminergic Medications and Clinical Outcomes in Huntington Disease: Evidence From the PROOF-HD Placebo-Controlled Trial.
Anderson KE, Tan AM, Feigin A, et al. · Neurology 2026
- Huntington's disease clinical trials update: August 2026.
Farag M, Kinyomi O, Tabrizi SJ, et al. · J Huntingtons Dis 2026
- A neuroprotective target in the shadows: a scoping review of pharmacological gaps in σ1R agonists for glutamate-induced neurotoxicity.
Xiang AQ, Thalmann M, Khanna I, et al. · Front Pharmacol 2026
- Pridopidine Mediated Sigma-1 Receptor Activation and Therapeutic Implications in Neurodegenerative Diseases.
Anwar AI, Hegazi AA, Bhuchakra HP, et al. · Neurol Int 2026
- Beyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review.
Wiprich MT, Pereira WD, Colonetti T, et al. · Eur J Pharmacol 2026
- Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial.
Geva M, Goldberg YP, Leitner ML, et al. · Amyotroph Lateral Scler Frontotemporal Degener 2026
Also in development for Amyotrophic Lateral Sclerosis
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- MN-166ibudilastPhase 31 trial
MediciNova · Amyotrophic Lateral Sclerosis
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
- BIIB147Phase 21 trial
Biogen · Amyotrophic Lateral Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.